Novartis used manipulated data in winning Zolgensma approval, FDA says

Novartis submitted manipulated data in its application to the Food and Drug Administration for the gene therapy Zolgensma, the agency revealed Tuesday, stating the drugmaker knew of the problem but failed to tell regulators before the treatment's approval.